Literature DB >> 16613964

Understanding the NSAID related risk of vascular events.

Harald E Vonkeman1, Jacobus R B J Brouwers, Mart A F J van de Laar.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16613964      PMCID： PMC1440616          DOI： 10.1136/bmj.332.7546.895

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  25 in total

Review 1.  The coxibs, selective inhibitors of cyclooxygenase-2.

Authors:  G A FitzGerald; C Patrono
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

2.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

3.  Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

Authors:  Gregory D Curfman; Stephen Morrissey; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

Review 4.  Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.

Authors:  Garret A FitzGerald
Journal:  Am J Cardiol       Date:  2002-03-21       Impact factor: 2.778

5.  Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

Authors:  J Page; D Henry
Journal:  Arch Intern Med       Date:  2000-03-27

Review 6.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

7.  Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis.

Authors:  E A J Knijff-Dutmer; E M Kalsbeek-Batenburg; J Koerts; M A F J van de Laar
Journal:  Rheumatology (Oxford)       Date:  2002-04       Impact factor: 7.580

8.  Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes.

Authors:  Y Tanaka; S L Ward; W L Smith
Journal:  J Biol Chem       Date:  1987-01-25       Impact factor: 5.157

9.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

Authors:  Elisabeth Ott; Nancy A Nussmeier; Peter C Duke; Robert O Feneck; R Peter Alston; Michael C Snabes; Richard C Hubbard; Ping H Hsu; Lawrence J Saidman; Dennis T Mangano
Journal:  J Thorac Cardiovasc Surg       Date:  2003-06       Impact factor: 5.209

10.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.

Authors:  G A FitzGerald; B Smith; A K Pedersen; A R Brash
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245
View more
  12 in total

1.  Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS.

Authors:  Steven Simoens; Sandra De Coster; Bernard De Ruyck; Petra Stutz; Gert Laekeman
Journal:  Pharm World Sci       Date:  2006-11-17

2.  Non-steroidal anti-inflammatory drugs after hip replacement.

Authors:  Fraser Birrell; Stefan Lohmander
Journal:  BMJ       Date:  2006-09-09

3.  Non-steroidal anti-inflammatory drugs and gastroprotection in primary health care users.

Authors:  Driton Shabani; Ardiana Murtezani; Bernard Tahirbegolli; Argjira Juniku-Shkololli; Zana Ibraimi
Journal:  Med Pharm Rep       Date:  2020-07-22

4.  Applications of the hexanic fraction of Agave sisalana Perrine ex Engelm (Asparagaceae): control of inflammation and pain screening.

Authors:  Ricardo José Dunder; Anderson Luiz-Ferreira; Ana Cristina Alves de Almeida; Felipe Meira de Faria; Christiane Takayama; Eduardo Augusto Rabelo Socca; Marcos José Salvador; Gláucia Coelho Mello; Catarina dos Santos; Pedro de Oliva-Neto; Alba Regina Monteiro Souza-Brito
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

Review 5.  Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.

Authors:  Inger L Meek; Mart A F J Van de Laar; Harald E Vonkeman
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-07

6.  Utilization of gastroprotective strategies for nonsteroidal anti-inflammatory drug-induced gastrointestinal events in a major teaching hospital.

Authors:  Hooi Leng Lee; Siew Siang Chua; Sanjiv Mahadeva
Journal:  Ther Clin Risk Manag       Date:  2016-11-10       Impact factor: 2.423

Review 7.  Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.

Authors:  Zoltan Varga; Syed Rafay Ali Sabzwari; Veronika Vargova
Journal:  Cureus       Date:  2017-04-08

8.  Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis.

Authors:  Piet Geusens; Willem Lems
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

9.  Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?

Authors:  Laurence Guy Howes
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

10.  Cardiovascular risk factor analysis in patients with a recent clinical fracture at the fracture liaison service.

Authors:  Caroline E Wyers; Lisanne Vranken; Robert Y van der Velde; Piet P M M Geusens; Heinrich M J Janzing; J Wim Morrenhof; Joop P W van den Bergh
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.